Searched for
BIOCON BUSINESS DIVESTMENT
Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...- I-Sec maintains Sell on Biocon, revises target price to Rs 270ICICI Securities maintains a 'Sell' call on Biocon, setting a revised target price of Rs 270. Despite a projected earnings CAGR of 91.6% dr...
- Biocon Q4 results: Net profit surges 153% at Rs 344 croreBiocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore. The company's bi...
- Biocon shares up 3% after US FDA nod for key cancer drugsBiocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, en...
- Stocks in news: DMart, ITC, Hero MotoCorp, Pricol, NHPCAvenue Supermarts, which operates retail chain DMart on Thursday reported a 17% year-on-year jump in its stanalone revenue for the quarter ...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- 'Biocon looking at options to cut debt taken for Viatris' business buy'"We are looking at a number of options to reduce that... I can say that you'll see the debt level coming down in the coming quarters," he s...
- Biocon reports Rs 42 crore net loss in Q3 due to exceptional itemThe biggest contribution came from the biosimilars business, which reported a 54% increase in revenues to Rs 1,507 crore. Research Services...
- True North set to buy 8-10% stake in Anthem for Rs 740 crTrue North will acquire about 8-10 per cent stake in Anthem Biosciences for Rs 740 crore ($75-100 million), at a valuation of $1 billion (R...
- We will get close to biosimilar guidance of $200 mn: Kiran Mazumdar Shaw, BioconIf there is a need to ramp up biosimilar development, we have many avenues to raise cash, says Shaw.
- Biocon rallies as Q1 net jumps 23% to Rs 126 croreShares of Biocon Ltd rallied 4.24% in intraday trade on Friday after the company reported a 23 per cent jump in Q1 net profit.
- Biocon Q1 net jumps 23 per cent to Rs 126 croreThe company's net sales grew by 15 per cent at Rs 857 crore for the period under review as compared to Rs 742 crore in the year-ago period,...
- Syngene IPO opens July 27; price band at Rs 240-250; Biocon shares end in redBiocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.
- Syngene IPO money to fund Biocon research: ShawShaw said that Biocon has the largest biosimilar pipeline globally in phase three clinical trials and the IPO will help fund those costs.
- Plan to list Syngene in August, use IPO proceeds for R&D: Kiran Mazumdar-ShawSyngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .
- Biocon logs smart recovery in fourth quarterAfter the divestment of Axicorp and the snapping of its biosimilar insulin deal with Pfizer, the company was expected to post a subdued per...
- Biocon picks up 70% in German pharma co AxiCorp for e30 mnThe deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.
- Biocon receives DCGI nod to market AbraxaneLeading biotech company Biocon Ltd has received approval from the Drug Controller General of India (DCGI) to market breast cancer drug Abra...
- Biocon completes divestment of its enzyme businessBiotechnology firm, Biocon on Monday said it has completed all activities related to the divestment of enzymes business to Novozymes South ...
- Biocon scouting for buyouts to boost businessBiocon Ltd may list its shares on international bourses in its effort to strengthen its pharmaceutical business.
Load More
